• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

FDA Approval of Paroxetine for Menopausal Hot Flushes
ABSTRACT: In June 2013, the Food and Drug Administration (FDA) approved paroxetine (Brisdelle, Noven) for the treatment of moderate to severe hot flushes (vasomotor symptoms) associated with menopause. Brisdelle is the only nonhormonal treatment approved by the FDA for this indication. Prior to approval of Brisdelle, FDA-approved treatments for hot flashes were hormones containing either estrogen alone or estrogen plus a progestin. Hormonal therapy is highly effective for treating vasomotor symptoms. However, the use of hormonal therapy dropped substantially after initial findings of the Women’s Health Initiative randomi...
Source: Obstetrical and Gynecological Survey - October 1, 2014 Category: OBGYN Tags: Gynecology: Office Gynecology Source Type: research

Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone only pill
ConclusionsThis is the first report of a new drospirenone only oral contraceptive providing clinical efficacy like combined oral contraceptives, with a good safety profile, and favourable cycle control.This article is protected by copyright. All rights reserved.
Source: Acta Obstetricia et Gynecologica Scandinavica - July 17, 2019 Category: OBGYN Authors: Santiago Palacios, Enrico Colli, Pedro ‐Antonio Regidor Tags: Original Research Article Source Type: research

Preoperative anemia and complications after surgery for pelvic organ prolapse: an analysis of the national surgical quality improvement program database
ConclusionsPreoperative anemia is associated with an increased risk of adverse postoperative outcomes in women having surgery for pelvic organ prolapse.
Source: International Urogynecology Journal - April 24, 2021 Category: OBGYN Source Type: research